WallStreetZenWallStreetZen

NASDAQ: ESLA
Estrella Immunopharma Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Estrella Immunopharma earnings were -$10.5M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest ESLA earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$2.1M, up 100.4% from last quarter. For the last reported fiscal year 2024 ending Jun 30, 2024, ESLA reported annual earnings of -$7.3M, with -34.2% growth.

ESLA earnings history

Current Revenue
$0.0
Current Earnings
-$10.5M
Current Profit Margin
0%

ESLA Return on Equity

Current Company
-1,258.2%
Current Industry
-60.2%
Current Market
31.5%
ESLA's Return on Equity (-1,258.2%)... subscribe to Premium to read more.
High Return on Equity Performance

ESLA undefined

Current Company
-304.4%
Current Industry
-2.5%
ESLA is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when ESLA announces earnings.

ESLA undefined

Current Company
572.42%
Current Industry
5.8%
ESLA has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

ESLA vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
ESLA-$10.48M-$10.48MN/A-$0.31
PYPD-$26.41M-$29.02M-97.54%$4.91
PLUR-$21.27M-$20.71MN/A-$3.62
LVTX-$29.00M-$31.51MN/A-$1.18
MDCX-$14.53M-$14.47MN/A-$1.42
View Top Biotech Stocks

Estrella Immunopharma Earnings Reports & History FAQ

What were Estrella Immunopharma's earnings last quarter?

Estrella Immunopharma (NASDAQ: ESLA) reported Q1 2025 earnings per share (EPS) of -$0.06, up 500% year over year. Total ESLA earnings for the quarter were -$2.10 million. In the same quarter last year, Estrella Immunopharma's earnings per share (EPS) was -$0.01.

If you're new to stock investing, here's how to buy Estrella Immunopharma stock.

Is Estrella Immunopharma profitable or losing money?

As of the last Estrella Immunopharma earnings report, Estrella Immunopharma is currently losing money. Estrella Immunopharma's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$10.48 million, a 72.06% increase year over year.

What was ESLA's earnings growth in the past year?

As of Estrella Immunopharma's earnings date in Q2 2025, Estrella Immunopharma's earnings has grown year over year. ESLA earnings in the past year totalled -$10.48 million.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.